Samsung Biologics, TG Therapeutics ink deal to mass produce MS hopeful ublituximab
As Samsung Biologics looks to dramatically scale its production with a $2 billion “super plant” in Incheon, South Korea, it’s signing on partners to fill its manufacturing schedule. Now, Samsung and TG Therapeutics will work together on manufacturing MS hopeful ublituximab.
“With the recent positive ULTIMATE I and II MS Phase 3 studies, we re-evaluated our supply needs and were very pleased we were able to secure the long-term capacity we believe we will need to meet the potential global demand for ublituximab,” TG CEO Michael Weiss said in a statement. “This is an important next step in our long-standing relationship with Samsung.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.